Cancer Res Treat. 2003 Oct;35(5):425-32. doi: 10.4143/crt.2003.35.5.425.
Replication-competent adenoviruses (Ads) are promising new modalities for the treatment of cancer. Selective replication of a viral agent in tumor may lead to improved efficacy over non-replicating Ads due to viral multiplication, lysis of the infected cancer cell and spread to surrounding cells. In our previous studies it was shown that the E1B 55 kD-deleted Ad (YKL-1) exhibits tumor specific replication and cell lysis, but with reduced cytolytic effects compared to the wild type adenovirus (Int J Cancer 2000;88: 454-463). Thus, improving the potency of oncolytic Ads remains an important goal for cancer gene therapy. To increase the oncolytic ability of YKL-1, an adenovirus death protein (ADP) gene was reintroduced under the control of a CMV or MLP promoter at the E3 region of the YKL-1, generating an YKL-cADP and YKL-mADP, respectively.
The in vitro cytolytic effect of ADP expressing Ads was evaluated by MTT assay, and the induction of apoptosis by ADP expressing Ads was examined by TUNEL analysis. Finally, the antitumor effect of ADP expressing Ads was demonstrated in C33A xenograft tumor model.
The YKL-cADP exerted a markedly enhanced cytolytic effect against H460 and SK-Hep1 cancer cell lines. The TUNEL assay indicated that the ADP-mediated cytotoxicity was largely driven by apoptosis. Finally, the YKL-cADP showed a superior antitumor effect than the YKL-1 or YKL-mADP in C33A xenografts.
These lines of evidence demonstrate that the YKL-cADP induces efficient cell lysis, which is critical for the addition of therapeutic value to replicating Ads in cancer gene therapy.
复制型腺病毒(Ads)是癌症治疗的新方法。病毒在肿瘤中的选择性复制可能会导致疗效提高,因为病毒的增殖、感染癌细胞的裂解和扩散到周围细胞。在我们之前的研究中,已经表明 E1B 55 kD 缺失的腺病毒(YKL-1)表现出肿瘤特异性复制和细胞裂解,但与野生型腺病毒相比,细胞毒性作用降低(Int J Cancer 2000;88:454-463)。因此,提高溶瘤腺病毒的效力仍然是癌症基因治疗的一个重要目标。为了提高 YKL-1 的溶瘤能力,在 YKL-1 的 E3 区域,在 CMV 或 MLP 启动子的控制下,重新引入了腺病毒死亡蛋白(ADP)基因,分别产生了 YKL-cADP 和 YKL-mADP。
通过 MTT 分析评估表达 ADP 的 Ads 的体外细胞溶解作用,并通过 TUNEL 分析检查表达 ADP 的 Ads 诱导的细胞凋亡。最后,在 C33A 异种移植肿瘤模型中证明了表达 ADP 的 Ads 的抗肿瘤作用。
YKL-cADP 对 H460 和 SK-Hep1 癌细胞系表现出明显增强的细胞溶解作用。TUNEL 分析表明,ADP 介导的细胞毒性主要是由细胞凋亡引起的。最后,YKL-cADP 在 C33A 异种移植瘤中表现出比 YKL-1 或 YKL-mADP 更好的抗肿瘤作用。
这些证据表明,YKL-cADP 诱导有效的细胞裂解,这对于在癌症基因治疗中增加复制型 Ads 的治疗价值至关重要。